Does LDN Help With Weight Loss? How It Differs From Contrave and GLP-1s
Low-dose naltrexone, commonly called LDN, appears in more weight-loss conversations than ever. Some patients report less appetite after starting it. Others assume that because naltrexone is one ingredient in Contrave, a lower dose of naltrexone must work as a gentler version of the FDA-approved weight-management medicine. Still others ask whether adding LDN to semaglutide or tirzepatide can accelerate results.
Those ideas sound connected. The clinical evidence does not support treating them as the same thing.
LDN is naltrexone used at a low dose for an off-label purpose. Contrave is a specific extended-release combination of naltrexone and bupropion that has been studied in large weight-management trials and approved by FDA. GLP-1-based medicines act through different pathways and have their own approved indications, prescribing information, benefits, and risks.
The most important answer is straightforward: LDN alone has not been established as a reliable weight-loss treatment, and there is no proven LDN plus GLP-1 strategy for enhanced weight loss.
Considering LDN or medical weight-management care? Explore Scripx low-dose naltrexone options and weight-management services. A licensed prescriber must determine whether a medication is appropriate, and LDN is not FDA-approved for weight loss.
Ready to Get Started?
Explore available treatment options and complete a secure health questionnaire for provider review.
View Products & Start Your Order →Prescription medications require an individual medical evaluation and, when appropriate, a prescription from a licensed healthcare provider. Completing a questionnaire does not guarantee treatment or a prescription.
The short answer: Does LDN cause weight loss?
There is no adequate evidence showing that typical low-dose naltrexone therapy consistently produces clinically meaningful weight loss in adults with obesity or overweight.
Naltrexone may affect appetite or food-reward pathways, and some individuals may notice a change in hunger, nausea, cravings, or eating behavior. An individual observation does not establish a reliable treatment effect. Weight can also change because pain improves, activity changes, another medication is started, dietary intake changes, or gastrointestinal side effects reduce food intake.
If weight loss occurs while taking LDN for another reason, that does not prove LDN is an effective obesity medication. The relevant question is whether naltrexone alone produces greater, sustained weight loss than placebo in appropriately designed clinical trials.
What did naltrexone-alone studies find?
The most useful direct obesity study is older, but its result remains relevant. In a double-blind trial, 60 adults with obesity were randomized to placebo or conventional naltrexone doses for eight weeks. Overall weight loss was not significantly different in either naltrexone group compared with placebo. A subgroup finding in women was reported, but the study was small, short, and not designed to establish modern LDN as an obesity treatment. It also used doses above what is commonly described as LDN.
A separate randomized study evaluated a lower naltrexone dose alongside nicotine replacement in people trying to stop smoking. At 26 weeks, the difference in post-cessation weight gain between naltrexone and placebo was not statistically significant. Smoking-cessation weight gain is not the same clinical question as treating obesity, but the result does not support broad weight-loss claims for low-dose naltrexone.
These studies do not prove that no person will ever experience appetite or weight changes. They do show why marketing LDN as a proven weight-loss medicine would go beyond the evidence.
Why Contrave is not the same as LDN
Contrave is an FDA-approved extended-release prescription product containing two active ingredients, naltrexone and bupropion. Bupropion is an aminoketone antidepressant with effects on norepinephrine and dopamine signaling. The combination was developed and studied as a combined treatment, not as interchangeable naltrexone monotherapy.
Current Contrave prescribing information indicates the medicine, together with reduced-calorie intake and increased physical activity, for long-term weight reduction and maintenance in eligible adults with obesity or overweight and at least one weight-related condition.
The approved product uses a specific extended-release formulation and treatment schedule. Its maintenance exposure includes substantially more naltrexone than most regimens commonly called LDN, plus a clinically meaningful amount of bupropion. Changing the ingredients, dose, release profile, or schedule creates a different treatment question.
This distinction matters for both efficacy and safety. Evidence supporting naltrexone plus bupropion cannot be transferred to low-dose naltrexone alone. It also cannot automatically be transferred to a separately compounded mixture.
What did the Contrave trials show?
Large randomized trials found that extended-release naltrexone plus bupropion produced greater average weight loss than placebo when used with lifestyle intervention.
In the COR-II trial, 1,496 adults with obesity or overweight and specified weight-related conditions were randomized to the combination or placebo. At 56 weeks, average weight change was greater with naltrexone plus bupropion than with placebo, and a larger proportion achieved at least 5 percent weight loss.
In COR-BMOD, 793 participants received intensive behavior modification plus either placebo or extended-release naltrexone and bupropion. The medication group lost more average weight at 56 weeks than the placebo group. The trial also illustrates an important point: medication was layered onto a structured behavioral program, not evaluated as a substitute for comprehensive care.
These results support the approved combination as labeled. They do not prove that naltrexone alone, LDN, or an LDN and bupropion regimen produces the same outcome.
LDN versus Contrave
| Question | Low-dose naltrexone | Contrave |
|---|---|---|
| Active ingredients | Naltrexone alone | Naltrexone plus bupropion |
| FDA status for weight management | Not approved | FDA-approved for eligible adults under its labeling |
| Formulation | Often patient-specific and compounded at a low strength | Fixed-dose extended-release commercial product |
| Direct weight-loss evidence | Inadequate for reliable efficacy claims | Supported by randomized weight-management trials |
| Can the evidence be shared? | No. Combination results do not prove LDN efficacy | Evidence applies to the studied combination and labeled use |
| Major shared safety issue | Opioid receptor blockade | Opioid receptor blockade plus bupropion-specific risks |
| Can they be taken together? | Requires medication reconciliation | Labeling says coadministration with other naltrexone-containing products is not recommended |
Can someone take LDN and Contrave together?
Contrave already contains naltrexone. Its prescribing information states that coadministration with other naltrexone-containing products is not recommended. Adding LDN would increase total naltrexone exposure without evidence that the combination improves weight loss.
Contrave is also contraindicated with other bupropion-containing products. This is one reason a clinician and pharmacist need the complete medication list, including brand names, generic names, compounded products, smoking-cessation medicines, and psychiatric medications.
Patients should not combine LDN with Contrave, add separate bupropion, or recreate an approved combination through self-directed dosing.
Contrave has safety considerations that LDN discussions may miss
Contrave carries a boxed warning related to suicidal thoughts and behaviors because it contains bupropion. It is not approved to treat major depressive disorder or other psychiatric conditions.
The current label lists important contraindications, including uncontrolled hypertension, seizure disorder or seizure history, bulimia or anorexia nervosa, chronic opioid use or acute opioid withdrawal, use of another bupropion-containing product, and use during or within the specified interval around a monoamine oxidase inhibitor. Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs also creates concern.
Blood pressure and heart rate should be monitored. Common adverse reactions include nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea. Pregnancy is not a setting for intentional weight loss, and the label instructs discontinuation when pregnancy is recognized.
This is not a complete safety review. It demonstrates why Contrave cannot be reduced to the statement, “It contains naltrexone.”
Where GLP-1 medicines fit
Semaglutide and tirzepatide are not forms of naltrexone. They work through incretin pathways involved in appetite, food intake, glucose regulation, and gastric emptying. Specific products have FDA-approved indications for chronic weight management and other conditions.
Current Wegovy prescribing information includes weight reduction and long-term weight maintenance indications for eligible patients, along with other product-specific indications. Current Zepbound prescribing information likewise includes long-term weight reduction and maintenance for eligible adults and additional product-specific use.
These medicines have randomized clinical-trial programs supporting their labeled uses. Results from one product or trial should not be assumed to apply to every GLP-1 medicine, every compounded preparation, or every patient.
Does adding LDN to a GLP-1 increase weight loss?
No adequate controlled evidence shows that adding LDN to semaglutide or tirzepatide produces more weight loss than appropriately prescribed GLP-1 therapy alone.
The absence of a widely recognized pharmacologic prohibition is not evidence of added benefit. When both medicines are prescribed, LDN should have a separate clinical rationale, such as an individualized off-label trial for another symptom or condition. Each medicine should have a defined target, monitoring plan, and stopping rule.
Starting both at the same time can also make side effects difficult to interpret. LDN may be associated with nausea, headache, sleep changes, vivid dreams, dizziness, or gastrointestinal symptoms. GLP-1-based medicines commonly produce gastrointestinal effects and can contribute to volume depletion when vomiting or diarrhea is persistent.
If appetite drops sharply, the goal is not simply to eat as little as possible. Weight-management care should consider adequate nutrition, protein intake, hydration, resistance activity when appropriate, and preservation of function. These decisions should be individualized by the treating team.
LDN plus a GLP-1 is not Contrave
LDN plus semaglutide or tirzepatide does not reproduce the naltrexone and bupropion combination in Contrave. The mechanisms, formulations, evidence, and safety profiles are different.
It is equally inaccurate to describe LDN as a “GLP-1 booster.” No established evidence shows that LDN prevents GLP-1 side effects, breaks a weight-loss plateau, preserves muscle, or enhances the metabolic effect of semaglutide or tirzepatide.
When online programs bundle medications, patients should ask what each component is intended to do and whether the combination itself has been studied.
What about compounded medications?
Compounding can meet a legitimate patient-specific need when an FDA-approved product is not medically appropriate for an identified patient. A compounded preparation is not FDA-approved, and FDA does not review it for safety, effectiveness, or quality before marketing.
A compounded low-dose naltrexone prescription is not an FDA-approved obesity treatment. A compounded product containing naltrexone and bupropion should not be marketed as a generic version of Contrave unless it has gone through the applicable FDA approval process. Changing a strength or dosage form also means that evidence from the approved product may not apply.
Scripx provides non-sterile patient-specific compounding when prescribed and appropriate. Scripx does not compound sterile GLP-1 injections. When weight-management care involves a compounded sterile medication supplied through another pharmacy, the dispensing and compounding roles should be clearly disclosed.
Learn more about personalized compounding and Scripx weight-management care.
Retatrutide is not an approved shortcut
Retatrutide is not FDA-approved. FDA states that retatrutide has not been found safe and effective for any condition and cannot be used in compounding under federal law. Products marketed online as compounded retatrutide or labeled “research use only” are not established patient-specific weight-loss therapies.
There is no evidence showing that retatrutide plus LDN is a safe or effective weight-loss combination. Patients should not substitute an unapproved product for an FDA-approved treatment plan.
The opioid interaction remains the non-negotiable LDN checkpoint
Naltrexone blocks opioid receptors. It can interfere with opioid pain relief and can precipitate acute withdrawal in a person with opioid dependence.
Opioid exposure includes more than commonly recognized prescription pain tablets. It may include tramadol, buprenorphine, methadone, certain cough medicines, certain diarrhea medicines, and medications used during or after a procedure.
Tell every prescriber, pharmacist, surgeon, dentist, anesthesia professional, and emergency clinician that you take naltrexone or LDN. Do not stop LDN, estimate a washout period, or attempt to overcome opioid blockade without direct medical guidance.
Review the Scripx guide to LDN drug interactions, opioids, and GLP-1s.
How to evaluate a weight change while taking LDN
If a patient starts LDN for a separate off-label purpose and weight changes, the care team should avoid assuming cause. A useful review includes:
-
Baseline weight and waist measurement, when clinically appropriate
-
Appetite, cravings, nausea, vomiting, diarrhea, and constipation
-
Dietary intake and hydration
-
Changes in pain, sleep, fatigue, and physical activity
-
Other new medications or dose changes
-
Menstrual, thyroid, glucose, or fluid-related factors when relevant
-
Functional strength and ability to maintain appropriate activity
-
A timeline showing when each change occurred
Unintentional, rapid, or unexplained weight loss requires evaluation. Weight change accompanied by persistent vomiting, severe abdominal pain, dehydration, weakness, bleeding, or other concerning symptoms should not be celebrated as medication success.
Questions to ask before choosing a medication
-
Is the goal weight management, treatment of another condition, or both?
-
Is this LDN, Contrave, an FDA-approved GLP-1 product, or a compounded medication?
-
Which evidence applies to this exact ingredient, dose, formulation, and indication?
-
Am I already taking naltrexone or bupropion under another name?
-
Do I use any opioid-containing medicine or have a procedure planned?
-
How will blood pressure, heart rate, mood, nutrition, hydration, and side effects be monitored?
-
What outcome should be achieved, and by when, for treatment to continue?
-
Which pharmacy is dispensing the medicine, and which pharmacy actually compounded it?
-
What should trigger a call to the clinic, medication reassessment, or urgent care?
Bottom line
LDN is not a proven weight-loss medicine. Naltrexone alone did not produce significant overall weight loss compared with placebo in a randomized obesity trial, and adequate evidence does not establish typical LDN therapy for obesity.
Contrave is different. It combines naltrexone with bupropion in a specific extended-release product supported by weight-management trials and an FDA-approved label. Its efficacy evidence and safety profile cannot be transferred to LDN alone.
GLP-1 medicines occupy another separate category. They may be appropriate for specific approved indications, but no controlled evidence shows that adding LDN enhances their weight-loss effect. Retatrutide remains unapproved and cannot be used in compounding under federal law.
The best medication choice is not the one with the most ingredients. It is the one with an appropriate indication, defensible evidence, a complete safety review, transparent pharmacy sourcing, and a monitoring plan built for the individual patient.
Explore your options with Scripx. Review low-dose naltrexone, explore weight-management care, or contact Scripx. Evaluation does not guarantee eligibility, treatment, or a prescription.
Medical disclaimer
This article is for general education and does not replace individualized medical advice. Do not start, stop, combine, or change LDN, Contrave, bupropion, a GLP-1 medicine, an opioid, or another prescription without guidance from a qualified clinician.
Frequently Asked Questions
Does LDN help you lose weight?
Adequate evidence does not show that LDN reliably produces clinically meaningful weight loss. Some people report appetite or weight changes, but those observations may be influenced by side effects, other medications, diet, activity, or improvement in another symptom.
Is LDN the same as Contrave?
No. LDN is low-dose naltrexone alone. Contrave is a specific extended-release combination of naltrexone and bupropion that is FDA-approved for long-term weight management in eligible adults.
Why does Contrave work if naltrexone alone does not?
Contrave was developed and studied as a two-drug combination. Bupropion contributes distinct pharmacologic effects, and the approved product uses a specific formulation and treatment schedule. Evidence for the combination does not prove that either ingredient produces the same result alone.
Can LDN reduce appetite or cravings?
Some individuals report appetite or craving changes, but there is no validated LDN response that reliably predicts weight loss. Nausea or reduced intake should not automatically be interpreted as a desirable therapeutic effect.
Can LDN and Contrave be taken together?
Contrave already contains naltrexone, and its prescribing information says coadministration with other naltrexone-containing products is not recommended. Patients should not combine them without direct medical direction.
Can LDN be taken with semaglutide or tirzepatide?
A prescriber may determine that both medicines are appropriate for separate goals after reviewing the patient’s history and medications. No controlled evidence establishes LDN plus semaglutide or tirzepatide as a superior weight-loss combination.
Does LDN make a GLP-1 work better?
There is no reliable evidence that LDN boosts GLP-1-related weight loss, prevents side effects, treats a plateau, or preserves muscle.
Is compounded LDN FDA-approved for weight loss?
No. LDN is not FDA-approved for weight loss, and a compounded LDN preparation is not FDA-approved.
Is compounded naltrexone and bupropion the same as generic Contrave?
Not automatically. A compounded preparation may differ in strength, release characteristics, inactive ingredients, quality review, and evidence. It should not be represented as an FDA-approved generic unless it has received the applicable approval.
Can someone use LDN while taking an opioid?
Naltrexone can block opioid pain relief and precipitate withdrawal in an opioid-dependent person. Patients should not combine LDN with an opioid or manage the transition without direct clinician guidance.
Is retatrutide approved for weight loss?
No. Retatrutide is not FDA-approved, and FDA states that it cannot be used in compounding under federal law.